Suppr超能文献

2019冠状病毒病有创通气患者的流行病学、通气管理及预后:对来自两大洲四个国家的四项观察性研究的分析

Epidemiology, Ventilation Management, and Outcomes in Invasively Ventilated Coronavirus Disease 2019 Patients: An Analysis of Four Observational Studies in Four Countries on Two Continents.

作者信息

Blok Siebe G, Pisani Luigi, Estenssoro Elisa, Ferreira Juliana Carvalho, Botta Michela, Motos Ana, Martin-Loeches Ignacio, Torres Antoni, Schultz Marcus J, Paulus Frederique, van Meenen David M P

机构信息

Department of Intensive Care, Amsterdam University Medical Center, Amsterdam, The Netherlands.

Mahidol Oxford Tropical Medicine Research Unit (MORU), Mahidol University, Bangkok, Thailand.

出版信息

Am J Trop Med Hyg. 2025 Jan 21;112(4):875-882. doi: 10.4269/ajtmh.24-0257. Print 2025 Apr 2.

Abstract

Epidemiology, ventilator management, and outcomes in patients with acute respiratory distress syndrome (ARDS) because of coronavirus disease 2019 (COVID-19) have been described extensively but have never been compared between countries. We performed an individual patient data analysis of four observational studies to compare epidemiology, ventilator management, and outcomes. We used propensity score weighting to control for confounding factors. The analysis included 6,702 patients: 1,500 from Argentina, 844 from Brazil, 975 from the Netherlands, and 3,383 from Spain. There were substantial differences in baseline characteristics between countries. There were small differences in ventilation management. Intensive care unit mortality was higher in Argentina and Brazil compared with the Netherlands and Spain (59.6% and 56.6% versus 32.1% and 34.7%; P <0.001). The median number of days free from ventilation and alive at day 28 was equally low (0 [0-7], 0 [0-18], 1 [0-16], and 0 [0-16] days, respectively; P = 0.03), and the median number of days free from ventilation and alive at day 60 was higher in the Netherlands and Spain (0 [0-37], 0 [0-50], 33 [0-48], and 26 [0-48] days, respectively; P <0.001). Propensity score matching confirmed the outcome differences. Thus, the outcome of COVID-19 ARDS patients in Argentina and Brazil was substantially worse compared with that of patients in the Netherlands and Spain. It is unlikely that this results from differences in case mix or ventilation management.

摘要

关于2019冠状病毒病(COVID-19)所致急性呼吸窘迫综合征(ARDS)患者的流行病学、呼吸机管理及预后情况已有大量描述,但各国之间从未进行过比较。我们对四项观察性研究进行了个体患者数据分析,以比较流行病学、呼吸机管理及预后情况。我们使用倾向评分加权法来控制混杂因素。该分析纳入了6702例患者:1500例来自阿根廷,844例来自巴西,975例来自荷兰,3383例来自西班牙。各国之间的基线特征存在显著差异。通气管理方面存在细微差异。与荷兰和西班牙相比,阿根廷和巴西重症监护病房的死亡率更高(分别为59.6%和56.6%,而荷兰和西班牙为32.1%和34.7%;P<0.001)。第28天无通气且存活的天数中位数同样较低(分别为0[0 - 7]天、0[0 - 18]天、1[0 - 16]天和0[0 - 16]天;P = 0.03),而第60天无通气且存活的天数中位数在荷兰和西班牙更高(分别为0[0 - 37]天、0[0 - 50]天、33[0 - 48]天和26[0 - 48]天;P<0.001)。倾向评分匹配证实了预后差异。因此,与荷兰和西班牙的患者相比,阿根廷和巴西COVID-19 ARDS患者的预后明显更差。这不太可能是由于病例组合或通气管理的差异所致。

相似文献

2
Positioning for acute respiratory distress in hospitalised infants and children.
Cochrane Database Syst Rev. 2022 Jun 6;6(6):CD003645. doi: 10.1002/14651858.CD003645.pub4.
3
Systemic corticosteroids for the treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Aug 16;8(8):CD014963. doi: 10.1002/14651858.CD014963.
4
Recruitment manoeuvres for adults with acute respiratory distress syndrome receiving mechanical ventilation.
Cochrane Database Syst Rev. 2016 Nov 17;11(11):CD006667. doi: 10.1002/14651858.CD006667.pub3.
5
Physical interventions to interrupt or reduce the spread of respiratory viruses.
Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6.
6
Early versus late tracheostomy in critically ill COVID-19 patients.
Cochrane Database Syst Rev. 2023 Nov 20;11(11):CD015532. doi: 10.1002/14651858.CD015532.
7
SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.
8
Early spontaneous breathing for acute respiratory distress syndrome in individuals with COVID-19.
Cochrane Database Syst Rev. 2022 Jun 29;6(6):CD015077. doi: 10.1002/14651858.CD015077.
9
Antibody tests for identification of current and past infection with SARS-CoV-2.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2.
10
Systemic corticosteroids for the treatment of COVID-19: Equity-related analyses and update on evidence.
Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD014963. doi: 10.1002/14651858.CD014963.pub2.

本文引用的文献

4
The Lancet Commission on lessons for the future from the COVID-19 pandemic.
Lancet. 2022 Oct 8;400(10359):1224-1280. doi: 10.1016/S0140-6736(22)01585-9. Epub 2022 Sep 14.
6
Major candidate variables to guide personalised treatment with steroids in critically ill patients with COVID-19: CIBERESUCICOVID study.
Intensive Care Med. 2022 Jul;48(7):850-864. doi: 10.1007/s00134-022-06726-w. Epub 2022 Jun 21.
8
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
Lancet. 2022 Feb 12;399(10325):629-655. doi: 10.1016/S0140-6736(21)02724-0. Epub 2022 Jan 19.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验